Andrea J. Kamage, an associate, has more than a decade of experience supporting the intellectual property needs of biotechnology and pharmaceutical companies. She has represented a highly diverse client base ranging from small biotech start ups to major international brand name and generic pharmaceutical corporations, as well as universities.
Ms. Kamage has expertise in patent counseling and procurement. Her practice encompasses domestic and foreign patent prosecution from drafting applications to advocating applications through issuance. She has significant experience in patentability, infringement, and validity opinions and has assisted clients in devising design-around strategies for issued patents. She has advised clients on licensing, materials transfer, and non-disclosure agreements. Additionally, she has conducted patent due diligence investigations for companies involved in corporate mergers and acquisitions. She has been involved in multiple pharmaceutical patent litigations brought under the Hatch-Waxman Act.
Ms. Kamage has experience with procuring or investigating patents related to genes and gene expression systems, proteins, antibodies, vaccines, small molecules, chemical synthesis, pharmaceutical formulations (capsules, tablets, orally disintegrating dosage forms, transdermal patches, injectables, and inhalation forms), drug delivery devices, methods of treatment with pharmaceuticals, orthopedic treatments, cosmetics, and bioinformatics.
Ms. Kamage is a frequent author on various aspects of intellectual property law, particularly on topics of concern to biotech and pharmaceutical companies. She is also an active member of the New Jersey Intellectual Property Law Association, serving as NJIPLA's Secretary for 2008.
Before law school, Ms. Kamage performed her graduate research in the area of tumor immunology at the National Institutes of Health, through a joint fellowship program with Genetics Department at The George Washington University. Prior to joining Lerner David, she was a patent agent and an associate at Sterne, Kessler, Goldstein & Fox in Washington, DC.
|
Education
| J.D., Georgetown University Law Center |
| M.S., Biology, The George Washington University |
| B.S., Biology, summa cum laude |
Bar Admissions
| New Jersey |
| District of Columbia |
| United States Patent & Trademark Office |
Publications and Presentations
| "Patent Due Diligence," The New Jersey Law Journal (April 20, 2007) |
| "Describing Biotech Inventions," The New Jersey Law Journal (May 29, 2006) |
| "Publishing Clinical Trial Data Could Affect Patents," The National Law Journal pp. S6-S7 (April 10, 2006) |
"Mars and Venus at the Patent Office," IP Law & Business pp. 26-30 (March 2006) |
| "The Patent Plague" IP Law & Business pp. 28-30 (August 2005) |
| "Chimeras: Patently Immoral?," The National Law Journal pp. S1-S7 (June 13, 2005) |
"The Blurry Biotech Line," IP Law & Business pp. 46-49 (June 2005); reprinted in Legal Times (June 20, 2005); Palm Beach Daily Business Review (June 22, 2005); Miami Daily Business Review (June 22, 2005); and Broward Daily Business Review (June 22, 2005) |
"The Medicare Modernization Act of 2003; The Effect on Entry of Generic Drugs into the Marketplace," The Intellectual Property Strategist 11(7):3-4 (April 2005) |
Affiliations
New Jersey Intellectual Property Law Association |
|